INTRODUCTION

Strict blood glycemic control is necessary for the management of diabetes. The latest guidelines recommend a level of HbA1c under 7% as a target goal for glycemic control [1,2]. Many clinicians prescribe diabetic patients intensified pharmacological treatments to maintain the HbA1c target goal. This can increase the risk of hypoglycemic events. Hypoglycemia is one of the most undesirable side effects in diabetic patients and can appear unpredictably. It primarily presents as iatrogenic hyperinsulinemia by insulin secretagogues or exogenous insulin. The more episodes of hypoglycemia a diabetic experiences, the more their defense mechanism against falling serum glucose is affected, resulting in increasing cycles of recurrent hypoglycemia. This study investigated the clinical characteristics, causal factors, and economic aspects of severely hypoglycemic patients with diabetes in an emergency room (ER) of Uijeongbu St. Mary's Hospital.

METHODS

Research design and methods

Study protocol was reviewed and approved by Institutional Review Board (IRB). This study retrospectively examined 320 hypoglycemic patients with diabetes presenting to the ER, all of whom were taking insulin or oral hypoglycemic agents. Data sources consisted of medical, pharmacy and laboratory records. Blood glucose tests were performed in all severely hypoglycemic patients in the ER. Estimated glomerular filtration rate (eGFR) was calculated using a formula based on the modification of diet in renal disease (MDRD). The medical costs of severe hypoglycemia in US dollars were determined to be the cost of hospitalization for 1 to 7 days ($46.90 to $328.30), the cost of diagnostic tests without and without brain imaging ($86.30 and $433 to $630, respectively), the cost of treatment administered ($6.60), assistance of a caregiver at the hospital for 1 to 7 days ($42.60 to $298.20), and transportation from patient's house to the hospital ($42.60 to $127.90). Severe hypoglycemia was defined as hypoglycemia that required an ER visit for treatment. Patients with an eGFR less than 60 mL/min/1.73 m² were considered to have stage 3 to 5 chronic kidney disease (CKD).

Statistical analysis

Data are presented as the mean±standard deviation. Differences between the groups were analyzed by ANOVA. Nominal variables were analyzed by chi-square test. P values less than 0.05 were considered statistically significant. All analyses were performed using SPSS version 12.0 (SPSS V12.0K; SPSS Inc., Chicago, IL, USA).

RESULTS

Most hypoglycemic patients presenting to the ER were elderly, with a mean age of 69.5±10.9 years old. Patients over 60 years old comprised 87.5% of the total number of patients (280/320) (Fig. 1). Mean glycemic control levels (HbA1c 7.0±1.5%) were near the latest guidelines. Serum creatinine levels and eGFR were 2.0±2.1 mg/dL and 48.0±33.6 mg/dL, respectively. Of the 320 patients, 188 (58.8%) had stage 3 to 5 CKD. Mean serum blood glucose levels as checked in the ER were 37.9±34.5 mg/dL. The number of hypoglycemic patients appears to increase every year (Table 1).

Table 2 shows the symptoms of severe hypoglycemia. The main presenting symptom of severe hypoglycemia was a decreased state of consciousness (86.3%, 276/320). Seventeen of the 276 hypoglycemic patients with a change in consciousness were in a persistent coma/stupor for ≥24 hours despite normalization of blood glucose levels and were ultimately discharged or transferred to another department.

Sulfonylureas and insulin increased the risk of severe hypoglycemia. Glimepiride-related severe hypoglycemia occurred more frequently than severe hypoglycemia associated with other sulfonylureas (Table 3).

Causal factors associated with hypoglycemia as reported by the patients were as follows: poor nutrition (73.4%, 235/320), change in medication or change in dose of current medication (12.5%, 40/320), alcohol intake (11.6%, 37/320), hemodialysis (4.4%, 14/320), and exercise (9%, 3/320). The most common problem reported was poor nutrition or missed meals.

Of the 320 patients, 242 (75.6%) were experiencing polypharmacy, which is the use of many different drugs not related to diabetes in patients who might have other health problems. Of the 235 patients who had poor nutrition, 65 of them (27.7%) experienced polypharmacy.

The total average medical cost in US dollars per severely hypoglycemic event was $135.50 to $1,391. The largest costs were from hospitalization and brain imaging studies.

DISCUSSION

Several guidelines emphasize the need for strict glycemic control to reduce diabetic complications, but this raises the risk of severe hypoglycemic events.

This study examined the clinical characteristics and causal factors associated with severe hypoglycemia in diabetic patients and also analyzed economic aspects. The present study defined severe hypoglycemia as requiring medical assistance in the ER, though severe hypoglycemia is usually defined as hypoglycemia requiring any type of medical treatment.

Most severe hypoglycemic events (87.5%, 280/320) occurred in patients greater than 60 years old. The most common cause of hypoglycemia was poor nutrition or a missed meal. Feher et al. [3] reported that precipitating causes of hypoglycemia were a missed meal (51%), alcohol intake, excess insulin, or exercise. These results support the findings of the present study. Poor nutrition in elderly patients can be caused masticatory problems, dysphagia, and problems preparing food due to hand tremors and visual problems [4]. Many of the patients (75.6%, 242/320) experienced polypharmacy not related to diabetes, which suggests multimorbidities. Polypharmacy in elderly multimorbid patients often includes anti-hypertensive drugs, anti-parkinsons drugs, anti-depressants and analgesics, all of which can cause decreased food intake [4]. Moreover, several anti-diabetics are associated with the decreased food intake [4]. It appears that polypharmacy due to multimorbidity has an indirect effect on severe hypoglycemia by reducing oral food intake.

The risk of hypoglycemia is particularly high in diabetic patients with renal impairment. It is estimated that 6 to 8 units of insulin are removed by the kidney daily, accounting for 25% to 40% of the removal of insulin [5]. The prevention of hypoglycemia in diabetic patients with renal failure or who are undergoing hemodialysis requires a 25% systematic reduction of exogenous insulin administration [6]. In this study, glycemic control (HbA1c 7.0±1.5%) in severely hypoglycemic patients was close to the goal established by the latest guidelines, and 58.8% (188/320) patients were stage 3 to 5 CKD. Sulfonylureas or insulin was associated with the incidence of severe hypoglycemia. Severe hypoglycemia associated with glimepiride occurred more frequently, correlating with higher doses of glimepiride. Long-acting sulfonylureas such as glimepiride and glibenclamide are associated with a higher risk of hypoglycemia in comparison to short-acting sulfonylureas. The metabolites of long-acting sulfonylureas are excreted renally, and in patients with renal impairment, even low doses of glimepiride (1 mg) can induce prolonged hypoglycemia lasting up to 64 hours [7]. Badian et al. [8] reported that the hepatic metabolites of glimepiride are hydroxyl-glimepiride, which is still associated with hypoglycemic activity, and carboxy-glimepiride. The active metabolite of hydroxyl-glimepiride (58%) is eliminated renally and carboxy-glimepiride (42%) is eliminated fecally. Thus, when treating elderly diabetic patients with renal impairment, low dose insulin or sulfonylureas should be administered to help prevent severe hypoglycemia.

Severe hypoglycemia has a significant impact on the total cost of treating diabetes. In this study, the largest average medical cost per severely hypoglycemic event was $1,385, which is approximately 1.35 times the annual treatment cost ($1,027) [9] for a diabetic patient without complications in Korea. The average medical costs per severely hypoglycemic event in other countries were $1,186 (US), €2,942 (Germany), €1,370 (Spain), €1,269 (UK), and €2806.8 (Sweden), and the cost of mild hypoglycemia was €26.0 (Sweden) [10-12]. Indirect costs that are often overlooked such as productivity and time lost should be considered when evaluating the costs of severe hypoglycemia. Patients with hypoglycemia had 77% more short-term disability days annually [13]. Reviriego et al. [14] reported that the overall mean cost of hypoglycemia is comprised of 65.4% direct costs and 34.6% indirect costs. The overall cost of hypoglycemia in 300,000 patients with type 2 diabetes in Sweden was estimated to be approximately €4,250,000 [12]. The economic burden of severe hypoglycemia in Korea might be greater than indicated in this study if indirect costs are also considered, such as missed work by the patient and by any family members who are caring for the patient.

This study is limited because it is retrospective and only included patients presenting to the ER in one health center. A nationwide survey is needed to more accurately evaluate the economic burden of diabetes, including indirect costs due to severe hypoglycemia in diabetic patients.

The incidence of severe hypoglycemia in diabetic patients is increasing due to stricter guidelines for managing diabetes. Severe hypoglycemia can impose an economic burden not only on the patients but also on the health care system. Moreover, severe hypoglycemia can induce permanent brain damage leading to a vegetative state. Therefore individualized goals for glycemic control are necessary. These goals should take into account factors such as the duration of diabetes, life expectancy, and comorbid conditions. More effective education for diabetic patients and their providers is also needed.

NOTES

No potential conflict of interest relevant to this article was reported.

REFERENCES

• 1. American Diabetes Association. Standards of medical care in diabetes--2012. Diabetes Care 2012;35(Suppl 1):S11-S63. ArticlePubMedPDF
• 2. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. American Diabetes Association. European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30. ArticlePubMedPDF
• 3. Feher MD, Grout P, Kennedy A, Elkeles RS, Touquet R. Hypoglycaemia in an inner-city accident and emergency department: a 12-month survey. Arch Emerg Med 1989;6:183-188. ArticlePubMedPMC
• 4. Pirlich M, Lochs H. Nutrition in the elderly. Best Pract Res Clin Gastroenterol 2001;15:869-884. ArticlePubMed
• 5. Schrier RW. Chapter 96, Metabolic and endocrine dysfunctions in uremia. Diseases of the kidney and urinary tract. 2007. 8th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; p. 2502-2539.
• 6. Sobngwi E, Enoru S, Ashuntantang G, Azabji-Kenfack M, Dehayem M, Onana A, Biwole D, Kaze F, Gautier JF, Mbanya JC. Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis. Diabetes Care 2010;33:1409-1412. ArticlePubMedPMCPDF
• 7. Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2003;111:405-414. ArticlePubMed
• 8. Badian M, Korn A, Lehr KH, Malerczyk V, Waldhausl W. Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration. Drug Metabol Drug Interact 1996;13:69-85. ArticlePubMed
• 9. Lee KW. Costs of diabetes mellitus in Korea. Diabetes Metab J 2011;35:567-570. ArticlePubMedPMC
• 10. Heaton A, Martin S, Brelje T. The economic effect of hypoglycemia in a health plan. Manag Care Interface 2003;16:23-27.
• 11. Brian MF. The economic costs of hypoglycemia. Br J Diabetes Vasc Dis 2011;11(1 Suppl):S10-S12.
• 12. Jonsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with type 2 diabetes in Sweden. Value Health 2006;9:193-198. ArticlePubMed
• 13. Rhoads GG, Orsini LS, Crown W, Wang S, Getahun D, Zhang Q. Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes. J Occup Environ Med 2005;47:447-452. ArticlePubMed
• 14. Reviriego J, Gomis R, Maranes JP, Ricart W, Hudson P, Sacristan JA. Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia. Int J Clin Pract 2008;62:1026-1032. ArticlePubMedPMC

Fig. 1

Age distribution of severe hypoglycemia. The number of severe hypoglycemic event is increasing according to age.

Table 1

Patient characteristics

Values are presented as mean±standard deviation or number (%). P values are obtained by ANOVA. N is the number of patients with available data per year and total.

GFR, glomerular filtration rate; CKD, chronic kidney disease; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

Table 2

Severe hypoglycemic symptoms

Values are presented as number (% of total number). N is the number of patients with available data.

Sx, symptom; Sn, sign.

Table 3

Administered oral hypoglycemic agents and insulin

Values are presented as number/total number (%). P value obtained by chi-square test for trend.

SU, sulfonylurea; INS, insulin.

^aOthers are oral hypoglycemic agents, except for sulfonylureas.

Figure & Data

References

Citations

Citations to this article as recorded by  

• The individualisation of glycaemic targets in response to patient characteristics in type 2 diabetes: a scoping review
  Samuel J Westall, Ram Prakash Narayanan, Simon Watmough, Greg Irving, Niall Furlong, Sid McNulty, Sumudu Bujawansa, Kevin Hardy
  Clinical Medicine.2022; 22(3): 257.     CrossRef
• Analysis of recurrent hypoglycemic events
  Chenchen Ma, Yongming Qu, Haoda Fu
  Journal of Biopharmaceutical Statistics.2021; 31(1): 5.     CrossRef
• ROLE OF OCTREOTIDE IN MANAGEMENT OF SULPHONYLUREA - INDUCED REFRACTORY HYPOGLYCEMIA : A CASE REPORT
  Akshay Kothari, Kiran Shah
  INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2021; : 3.     CrossRef
• Hospitalization Costs Due to Hypoglycemia in Patients with Diabetes: A Microcosting Approach
  João P. Ferreira, Francisco Araújo, Jorge Dores, Lèlita Santos, Estevão Pape, Mónica Reis, Árcia Chipepo, Edite Nascimento, Ana Baptista, Vanessa Pires, Carlos Marques, Adriana S. Lages, João Conceição, Pedro A. Laires, João Pelicano-Romano, Sílvia Alão
  Diabetes Therapy.2020; 11(10): 2237.     CrossRef
• The Burden of Hypoglycemia in Patients With Insulin-Treated Diabetes Mellitus in China: Analysis of Electronic Medical Records From 4 Tertiary Hospitals
  Xiaomeng Yue, Jiuhong Wu, Zhen Ruan, Michael L. Wolden, Lanting Li, Yong Lin
  Value in Health Regional Issues.2020; 21: 17.     CrossRef
• A closer look at the 2019 Beers criteria
  Rishabh Sharma, Malika Arora, Ravinder Garg, Parveen Bansal
  Drugs & Therapy Perspectives.2020; 36(3): 116.     CrossRef
• Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control
  Jee Hee Yoo, Jae Hyeon Kim
  Diabetes & Metabolism Journal.2020; 44(6): 828.     CrossRef
• Comparison of clinical pharmacy specialists and usual care in outpatient management of hyperglycemia in Veterans Affairs medical centers
  Heather L Ourth, Kwan Hur, Anthony P Morreale, Francesca Cunningham, Bharat Thakkar, Sherrie Aspinall
  American Journal of Health-System Pharmacy.2019; 76(1): 26.     CrossRef
• Cost‐effectiveness of the psycho‐educational blended (group and online) intervention HypoAware compared with usual care for people with Type 1 and insulin‐treated Type 2 diabetes with problematic hypoglycaemia: analyses of a cluster‐randomized controlled
  M. de Wit, S. M. P. A. Rondags, M. W. van Tulder, F. J. Snoek, J. E. Bosmans
  Diabetic Medicine.2018; 35(2): 214.     CrossRef
• Dynamin-related protein 1 mediates low glucose-induced endothelial dysfunction in human arterioles
  Michael J. Tanner, Jingli Wang, Rong Ying, Tisha B. Suboc, Mobin Malik, Allison Couillard, Amberly Branum, Venkata Puppala, Michael E. Widlansky
  American Journal of Physiology-Heart and Circulatory Physiology.2017; 312(3): H515.     CrossRef
• Hazardous factors besides infection in hypoglycemia
  Yu-Jang Su, Yen-Chun Lai, Chia-Jung Liao
  Biomedical Reports.2017; 6(4): 480.     CrossRef
• Economic Burden of Hypoglycemia in Patients with Type 2 Diabetes Mellitus from Korea
  Gyuri Kim, Yong-ho Lee, Mi Hye Han, Eui-Kyung Lee, Chong Hwa Kim, Hyuk Sang Kwon, In Kyung Jeong, Eun Seok Kang, Dae Jung Kim, Massimo Pietropaolo
  PLOS ONE.2016; 11(3): e0151282.     CrossRef
• Costs associated with emergency care and hospitalization for severe hypoglycemia
  G. Veronese, G. Marchesini, G. Forlani, S. Saragoni, L. Degli Esposti, E. Centis, A. Fabbri
  Nutrition, Metabolism and Cardiovascular Diseases.2016; 26(4): 345.     CrossRef
• Risk of hospitalization for hypoglycemia among older Korean people with diabetes mellitus
  Hyun Min Kim, Jong-Mi Seong, Jaetaek Kim
  Medicine.2016; 95(42): e5016.     CrossRef
• Risk factors of severe hypoglycemia requiring medical assistance and neurological sequelae in patients with diabetes
  Ja Young Jeon, Se Ran Kim, Hae Jin Kim, Dae Jung Kim, Kwan-Woo Lee, Jung-Dong Lee, Seung Jin Han
  Medicine.2016; 95(47): e5365.     CrossRef
• Effectiveness of HypoAware, a Brief Partly Web-Based Psychoeducational Intervention for Adults With Type 1 and Insulin-Treated Type 2 Diabetes and Problematic Hypoglycemia: A Cluster Randomized Controlled Trial
  Stefanie M.P.A. Rondags, Maartje de Wit, Jos W. Twisk, Frank J. Snoek
  Diabetes Care.2016; 39(12): 2190.     CrossRef
• The cost of managing severe hypoglycemic episodes in Type 2 diabetic patients
  Pedro Almeida Laires, João Conceição, Francisco Araújo, Jorge Dores, Catarina Silva, Larry Radican, Ana Nogueira
  Expert Review of Pharmacoeconomics & Outcomes Research.2016; 16(2): 315.     CrossRef
• HypoAware: development and pilot study of a brief and partly web‐based psychoeducational group intervention for adults with Type 1 and insulin‐treated Type 2 diabetes and problematic hypoglycaemia
  S. M. P. A. Rondags, M. de Wit, F. J. Snoek
  Diabetic Medicine.2016; 33(2): 184.     CrossRef
• Hypoglycemia and Health Costs
  Yong-ho Lee, Gyuri Kim, Eun Seok Kang
  The Journal of Korean Diabetes.2016; 17(1): 11.     CrossRef
• Avoiding or coping with severe hypoglycemia in patients with type 2 diabetes
  Jae-Seung Yun, Seung-Hyun Ko
  The Korean Journal of Internal Medicine.2015; 30(1): 6.     CrossRef
• 1,5-Anhydroglucitol as a Useful Marker for Assessing Short-Term Glycemic Excursions in Type 1 Diabetes
  Hannah Seok, Ji Hye Huh, Hyun Min Kim, Byung-Wan Lee, Eun Seok Kang, Hyun Chul Lee, Bong Soo Cha
  Diabetes & Metabolism Journal.2015; 39(2): 164.     CrossRef
• Intensive Individualized Reinforcement Education Is Important for the Prevention of Hypoglycemia in Patients with Type 2 Diabetes
  Yun-Mi Yong, Kyung-Mi Shin, Kang-Min Lee, Jae-Young Cho, Sun-Hye Ko, Min-Hyang Yoon, Tae-Won Kim, Jong-Hyun Jeong, Yong-Moon Park, Seung-Hyun Ko, Yu-Bae Ahn
  Diabetes & Metabolism Journal.2015; 39(2): 154.     CrossRef
• Hypoglycaemia in elderly patients with type 2 diabetes mellitus: a review of risk factors, consequences and prevention
  Badieh Jafari, Mary E. Britton
  Journal of Pharmacy Practice and Research.2015; 45(4): 459.     CrossRef
• HypoAware-a brief and partly web-based psycho-educational group intervention for adults with type 1 and insulin-treated type 2 diabetes and problematic hypoglycaemia: design of a cost-effectiveness randomised controlled trial
  Stefanie MPA Rondags, Maartje de Wit, Maurits W van Tulder, Michaela Diamant, Frank J. Snoek
  BMC Endocrine Disorders.2015;[Epub]     CrossRef
• Hypoglycemia in Emergency Department
  Yu-Jang Su, Chia-Jung Liao
  Journal of Acute Disease.2015; 4(1): 59.     CrossRef
• Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? Yes, They Continue to Serve Us Well!
  Martin J. Abrahamson
  Diabetes Care.2015; 38(1): 166.     CrossRef
• Association Between Hypoglycemia and Fall-Related Events in Type 2 Diabetes Mellitus: Analysis of a U.S. Commercial Database
  Sumesh Kachroo, Hugh Kawabata, Susan Colilla, Lizheng Shi, Yingnan Zhao, Jayanti Mukherjee, Uchenna Iloeje, Vivian Fonseca
  Journal of Managed Care & Specialty Pharmacy.2015; 21(3): 243.     CrossRef
• Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes
  Robert R. Henry, Julio Rosenstock, Douglas Logan, Thomas Alessi, Kenneth Luskey, Michelle A. Baron
  Journal of Diabetes and its Complications.2014; 28(3): 393.     CrossRef
• Management of Diabetes Medications for Patients Undergoing Ambulatory Surgery
  Mary Ann Vann
  Anesthesiology Clinics.2014; 32(2): 329.     CrossRef
• Principales factores asociados al coste de la diabetes mellitus tipo 2: revisión de la literatura
  Silvia Paz, Diego González Segura, Anna Raya Torres, Luis Lizan
  Avances en Diabetología.2014; 30(2): 34.     CrossRef
• Incidence of hypoglycaemia associated with transient loss of consciousness. A retrospective cohort study
  A. Lagi, S. Cencetti, F. Lagi
  International Journal of Clinical Practice.2014; 68(8): 1029.     CrossRef
• Hypoglycemia in Patients with Type 1 Diabetes: Epidemiology, Pathogenesis, and Prevention
  Omodele Awoniyi, Rabia Rehman, Samuel Dagogo-Jack
  Current Diabetes Reports.2013; 13(5): 669.     CrossRef
• Diabetes: support for those at risk of malnutrition in the community
  Siobhan Hughes
  British Journal of Community Nursing.2012; 17(11): 529.     CrossRef
• Diabetes patients at risk of malnutrition
  Siobhan Hughes
  Independent Nurse.2012;[Epub]     CrossRef
• Type 2 diabetes: the evolution of a disease
  Harold E Lebovitz
  The British Journal of Diabetes & Vascular Disease.2012; 12(6): 290.     CrossRef
• Severe Hypoglycemia in Patients with Diabetes
  Jae Seung Yun, Seung-Hyun Ko
  Diabetes & Metabolism Journal.2012; 36(4): 273.     CrossRef

About this article

Ha WC, Oh SJ, Kim JH, Lee JM, Chang SA, Sohn TS, Son HS. Severe Hypoglycemia Is a Serious Complication and Becoming an Economic Burden in Diabetes. Diabetes Metab J. 2012;36(4):280-284.

Received: May 16, 2012; Accepted: Jun 22, 2012

DOI: https://doi.org/10.4093/dmj.2012.36.4.280.

Download citation ↓